Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV.
Raltegravir (formerly known as MK-0518; Isentress) is the first in a new class of integrase inhibitors approved for the use in treatment-experienced adult patients who have evidence of viral replication and HIV strains resistant to multiple antiretroviral agents. It is dosed twice daily with or without food. Raltegravir is a novel antiretroviral that has been shown to be well tolerated. It has demonstrated potent efficacy in the virologic suppression of HIV-1 RNA levels up to 48 weeks in two controlled studies that were conducted in clinically advanced, three-class antiretroviral, treatment-experienced adults.
Sayana
Shilpa
S
Department of Medicine, AIDS Healthcare Foundation, Los Angeles, CA, USA.
Khanlou
Homayoon
H
D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D011760:Pyrrolidinones / Q000737:chemistry / Q000494:pharmacology*; D000068898:Raltegravir Potassium
D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium